PCVX · XBRL financial data

Vaxcyte financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PCVX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	97	104*	95	132	117	134*	148	194	210	242*	313	268
General and administrative	16	18*	20	21	23	29*	33	32	32	32*	33	35
Total operating expenses	113	197*	114	153	140	162*	181	226	242	274*	346	303
Operating income (loss)	(113)	(197)*	(114)	(153)	(140)	(162)*	(181)	(226)	(242)	(274)*	(346)	(303)
Interest income	18	18*	22	24	28	36*	33	31	29	26*	27	26
Interest expense	0	0*	—	—	—	year only	—	—	—	—	—	—
Other income (expense)	20	16*	19	24	37	25*	7	29	0	1*	(1)	(7)
Income tax expense (benefit)	0	0*	0	0	0	0*	0	0	0	0*	0	0
Net income (loss)	(93)	(181)*	(95)	(129)	(103)	(137)*	(141)	(167)	(213)	(247)*	(321)	(284)
Earnings per share, basic USD per share	(0.91)	(1.76)*	(0.85)	(1.10)	(0.83)	(1.01)*	(1.04)	(1.22)	(1.56)	(1.81)*	(2.30)	(1.97)
Earnings per share, diluted USD per share	(0.91)	(1.76)*	(0.85)	(1.10)	(0.83)	(1.01)*	(1.04)	(1.22)	(1.56)	(1.81)*	(2.30)	(1.97)
Weighted average shares, basic millions of shares	102	102*	112	117	124	135*	136	136	136	136*	140	144
Weighted average shares, diluted millions of shares	102	102*	112	117	124	135*	136	136	136	136*	140	144

Fiscal quarters (PCVX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	545	397	612	519	1,050	388	347	307	281	174	261	183
Short-term investments	721	683	875	934	1,130	1,359	1,325	1,355	1,430	1,387	1,476	1,304
Prepaid and other current assets	30	16	31	29	33	41	45	54	56	66	76	66
Total current assets	1,295	1,096	1,517	1,481	2,214	1,788	1,717	1,716	1,767	1,627	1,813	1,553
Property and equipment, net	11	80	85	126	163	198	217	242	253	257	261	260
Right-of-use asset	16	31	29	27	29	72	88	86	84	116	113	110
Total assets	1,496	1,408	2,091	2,087	3,560	3,511	3,378	3,305	3,172	3,003	3,348	3,138
Accounts payable	16	15	22	10	18	48	21	31	49	71	63	101
Accrued liabilities	15	60	54	22	31	29	26	32	25	31	30	25
Total current liabilities	86	145	87	83	124	140	97	154	200	206	242	271
Lease liability, non-current	8	22	20	18	18	65	81	80	79	111	110	109
Total liabilities	93	167	107	101	142	205	178	234	279	317	352	380
Accumulated deficit	(744)	(924)	(1,019)	(1,148)	(1,251)	(1,388)	(1,529)	(1,696)	(1,908)	(2,155)	(2,476)	(2,760)
Total stockholders' equity	1,403	1,240	1,984	1,986	3,418	3,306	3,200	3,071	2,893	2,686	2,996	2,758
Total liabilities and equity	1,496	1,408	2,091	2,087	3,560	3,511	3,378	3,305	3,172	3,003	3,348	3,138
Common shares outstanding (cover page) millions of shares	95	108	109	112	125	129	129	130	131	144	144	149

Fiscal quarters (PCVX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(93)	(181)*	(95)	(129)	(103)	(137)*	(141)	(167)	(213)	(247)*	(321)	(284)
Stock-based compensation	13*	13*	18	22*	21*	24*	31	37*	35*	36*	38	41*
Depreciation and amortization	1*	1*	1	1*	2*	3*	3	3*	3*	7*	3	3*
Net cash from operating activities	(58)*	(129)*	(159)	(121)*	(61)*	(111)*	(166)	(121)*	(143)*	(225)*	(281)	(232)*
Purchases of property and equipment	7*	5*	6	8*	5*	4*	5	2*	4*	3*	2	4*
Net cash from investing activities	22*	(14)*	(451)	(80)*	(917)*	(557)*	123	78*	121*	115*	(233)	148*
Proceeds from issuing common stock	49*	(0)*	0	107*	89*	(0)*	—	—	—	—	—	—
Net cash from financing activities	49*	3*	818	110*	1,515*	5*	1	3*	(4)*	2*	602	6*
Net change in cash	14*	(148)*	214	(93)*	532*	(662)*	(41)	(40)*	(26)*	(107)*	87	(78)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Ultragenyx Pharmaceutical	125	214	(97)*	98.6M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Avidity Biosciences	383	0.9*	(170)*	155.1M	2.3 quarters	Q4 FY25 10-KDec 31, 2025
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.